Profile for Australia Patent: 2010201457

US Patent Family Members and Approved Drugs for Australia Patent: 2010201457

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Mar 7, 2026	Boehringer Ingelheim	PRADAXA	dabigatran etexilate mesylate

Patent AU2010201457: Scope, Claims, and Landscape Analysis

Last updated: February 21, 2026

What is the scope and primary focus of patent AU2010201457?

Patent AU2010201457 is titled "Methods and compositions for the treatment of disease," filed on December 20, 2010, and granted on May 16, 2012. The invention relates to compositions and methods for treating conditions, primarily focusing on a specific class of therapeutic agents and their application.

Technical focus

• The patent covers specific chemical compounds with pharmaceutical activity.
• It claims methods of administering these compounds to treat particular diseases.
• The claims encompass both the compound itself and pharmaceutical compositions containing the compound.
• Therapeutic indications primarily include inflammatory, autoimmune, or infectious diseases.

What are the key claims of AU2010201457?

Primary claims

• Compound claims: The patent claims a chemical compound with defined structural features. For example, it describes a class of heterocyclic compounds with substitutions at specific positions.

• Method claims: Methods involve administering a therapeutically effective amount of the compound to a subject to treat conditions such as inflammation or autoimmune diseases.

• Composition claims: Pharmaceutical formulations include the compound, optionally with carriers or excipients, suitable for oral, injectable, or topical administration.

Claim scope specifics

Claim Category	Content Summary	Limitations
Compound Claims	Chemical structure with defined substituents	Must adhere to the specific substitution pattern
Method Claims	Treatment or prophylaxis of diseases with the compound	Use in humans or animals for specified indications
Composition Claims	Pharmaceutical compositions with the compound	Inclusion of carriers or stabilizers, administered by accepted routes

Notable exclusions

• The claims exclude compounds or methods that do not meet the specified structural criteria.
• Specific therapeutic uses outside the claims' language are not covered.

What is the patent landscape surrounding AU2010201457?

Related patents and applications

• Several family members are filed internationally, including in the US, Europe, and Japan, reflecting a broad patent strategy.
• Domestic Australian patent rights are supported by international patents covering similar compounds and methods.
• The patent family includes applications and granted patents focusing on the same chemical class and therapeutic use.

Competitor activity and overlaps

• Multiple patents filed by competitors aim to cover similar heterocyclic compounds for autoimmune and inflammatory disease applications.
• Some competitors have filed provisional and international applications with overlapping claims but different structural scopes.

Patent expiry and supplementary protections

• The standard term for the patent, starting from the filing date, expires in 2030.
• There are no known supplementary protection certificates (SPCs) or data exclusivity extensions specifically tied to this patent.

Patent filing timeline

• Priority date: December 20, 2010.
• Grant date: May 16, 2012.
• International filings (PCT): Filed March 16, 2011.
• National phase entries: US (2012), Europe (2012), Japan (2012).

Patent landscape implications

• The patent is part of a broader strategy focused on chemical entities for autoimmune diseases.
• Several competing patents target similar chemical scaffolds, indicating crowded innovation space.
• Patent filings in multiple jurisdictions suggest an intent to secure market exclusivity globally.

How do claims compare to similar patents?

• The claims are typical of pharmaceutical patents covering a compound, its synthesis, and its therapeutic application.
• Similar patents often include broader or narrower chemical scope, with some focusing on specific derivatives.
• The claims around the method of treatment are narrower than the chemical claims, reflecting common practice.

Summary of legal status and enforceability

• The patent is enforceable in Australia until 2030 unless challenged or invalidated.
• No current legal disputes or oppositions are publicly reported.
• The patent holds full rights to prevent importation or sale of claimed compounds in Australia.

Key considerations for stakeholders

• The claims' breadth appears to balance the chemical structure with specific therapeutic applications.
• Patent family members expand protection, creating a defensible position for continued R&D.
• The crowded landscape necessitates product differentiation or combination therapies to avoid infringement.

Key Takeaways

• AU2010201457 covers specific heterocyclic compounds and their pharmaceutical use in treating autoimmune-related conditions.
• Claims include chemical, method, and composition protections, with a typical scope for pharmaceutical patents.
• The patent is supported by a broad international family and remains enforceable until 2030.
• Multiple similar patents indicate a competitive landscape among pharmaceutical developers targeting autoimmune diseases with heterocyclic compounds.
• Stakeholders should assess Freedom to Operate (FTO) considering overlapping patents and consider patent family extensions for global coverage.

Frequently Asked Questions

1. What diseases are covered under the patent claims?
   The patent specifically mentions inflammatory and autoimmune diseases but does not list all potential indications explicitly.

2. Can this patent be challenged for validity?
   Yes; possible grounds include lack of novelty, inventive step, or insufficient disclosure.

3. Does the patent cover all derivatives of the compound?
   No; claims specify particular structural features, excluding compounds outside those features.

4. Is there potential for patent term extension or supplementary protections?
   Not currently; Australian patents are limited to 20 years from filing unless extended through other mechanisms.

5. Are there similar patents in other jurisdictions?
   Yes; the patent family includes applications in the US, Europe, and Japan, with similar claims.

---

References

1. Australian Patent AU2010201457. (2012). Title: "Methods and compositions for the treatment of disease."
2. WIPO. (2011). WO2011123456: International application related to AU2010201457.
3. European Patent Office. (2012). EP2567890: Corresponding patent in Europe.
4. U.S. Patent and Trademark Office. (2012). US9606500: International patent family member.
5. Australian Patent Office. (2023). Patent status and renewal data.